Harbor Investment Advisory LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 69.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,406 shares of the medical research company's stock after purchasing an additional 578 shares during the quarter. Harbor Investment Advisory LLC's holdings in IQVIA were worth $305,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Riverview Trust Co bought a new position in IQVIA in the first quarter worth $25,000. Dividend Assets Capital LLC bought a new position in IQVIA in the first quarter worth $27,000. Johnson Financial Group Inc. bought a new position in IQVIA in the fourth quarter worth $34,000. Quent Capital LLC lifted its holdings in shares of IQVIA by 271.8% during the first quarter. Quent Capital LLC now owns 145 shares of the medical research company's stock valued at $34,000 after acquiring an additional 106 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of IQVIA by 243.2% during the first quarter. EverSource Wealth Advisors LLC now owns 151 shares of the medical research company's stock valued at $35,000 after acquiring an additional 107 shares during the period. 86.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Guggenheim lifted their price objective on IQVIA to $246.00 in a report on Friday, July 22nd. Morgan Stanley lifted their price objective on IQVIA from $255.00 to $260.00 and gave the company an "overweight" rating in a report on Friday, July 22nd. Evercore ISI lifted their price objective on IQVIA from $265.00 to $275.00 in a report on Friday, July 22nd. Credit Suisse Group began coverage on IQVIA in a report on Wednesday, August 24th. They set an "outperform" rating and a $300.00 price objective for the company. Finally, Robert W. Baird raised their target price on IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $275.00.

IQVIA Price Performance

IQVIA (NYSE:IQV – Get Rating) last announced its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $2.21 by $0.04. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.49 billion. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. The company's revenue was up 3.0% on a year-over-year basis. During the same period last year, the company earned $1.94 earnings per share. Research analysts expect that IQVIA Holdings Inc. will post 9.4 EPS for the current year.

About IQVIA

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

• Get a free copy of the StockNews.com research report on IQVIA (IQV)
• MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Is the Market Overreacting with Shopify Stock?
• MO Money: Why Altria Group Stock is Rallying
• Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Three Consumer Stocks That Could Outperform In Q4

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.